Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Trilogy Laboratories, LLC
WARNING LETTER
•Trilogy Laboratories, LLC•August 27, 2019

Trilogy Laboratories, LLC – FDA Warning Letter, Aug 27, 2019

Record Details

The FDA inspected Trilogy Laboratories, LLC from August 22-27, 2019, identifying significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals (21 CFR parts 210 and 211). Consequently, the firm's drug products are adulterated under section 501(a)(2)(B) of the FD&C Act. Specific CGMP violations included failure to perform appropriate laboratory testing for drug product release, failure to verify component identity and validate supplier analyses, and inadequate written procedures for production and process control.

Additionally, several products were cited for unapproved new drug and misbranding violations. “AZUL Gly Sal Pads,” “AZUL Acne Defense Cream,” and “Azul DermaBright HQ Serum” are unapproved new drugs, violating section 505(a) of the FD&C Act, as they are not generally recognized as safe and effective and lack FDA approval. These products, along with “AZUL Gly Sal Pads” and “AZUL Acne Defense Serum,” are also misbranded under section 502(c) for failing to include a Drug Facts panel. “Azul DermaBright HQ Serum,” “daily eclipse tinted Broad Spectrum SPF 30,” and “daily eclipse Broad Spectrum SPF 30” are misbranded under section 502(x) for lacking a domestic address or phone number for adverse event reporting. Furthermore, “AZUL Satin Eclipse Broad Spectrum SPF 32” is misbranded under section 502(a) due to false and misleading SPF labeling.

The firm's September 18, 2019, response to the FDA 483 was deemed inadequate. The FDA acknowledges the firm's commitment to cease drug production but requires clarification on future manufacturing plans. The firm must promptly correct all cited violations within 15 working days, providing a detailed response and schedule. Failure to comply may lead to legal action, including seizure and injunction, and impact federal contracts or product approvals. A face-to-face regulatory meeting will be scheduled to ensure corrective actions.

Company
Trilogy Laboratories, LLC
Inspection date
August 27, 2019
Product type
Drugs
Office
Office of Pharmaceutical Quality Operations Division I
People
  • Monica R. Maxwell (Program Division Director)
  • Jessica Sapp
View Company Profile

ID · ae30ca41-88f8-41ef-a662-4ae79761a6b8

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.165(a)21 CFR 211.165(b)21 CFR 211.84(d)(1)21 CFR 211.84(d)(2)21 CFR 211.100(a)21 CFR 201.12821 CFR 201.66(b)(2)

Full citation text and observation details available on the Dashboard.

Other documents for Trilogy Laboratories, LLC
  • 483 - 2019-08-27August 27, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Trilogy Laboratories, LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.